Kaan Z Apaydin1, Holly B Fontenot2, Christina P C Borba3, Derri L Shtasel4, Sharon Ulery1, Kenneth H Mayer5, Alex S Keuroghlian6. 1. The Fenway Institute, United States. 2. The Fenway Institute and Boston College, United States. 3. Boston University, School of Medicine and Boston Medical Center, United States. 4. Harvard Medical School and Massachusetts General Hospital, United States. 5. The Fenway Institute, Beth Israel Deaconess Medical Center, United States. 6. The Fenway Institute, Harvard Medical School, and Massachusetts General Hospital, United States. Electronic address: akeuroghlian@partners.org.
Abstract
BACKGROUND: Disparities in human papillomavirus (HPV) vaccination completion have been noted among sexual and gender minority (SGM) people. Little is known about factors associated with HPV vaccination among SGM people. This study examines factors linked with completion of HPV vaccination among SGM patients. METHODS: We collected cross-sectional data from electronic health records (EHRs) of SGM patients receiving primary care at a Boston community health center specialized in SGM health. We employed a binomial logistic regression model to identify factors associated with 3-dose HPV vaccine completion. RESULTS: Patients were 70.3% white, with mean age of 26.3 years (SD = 2.48), 26.9% identifying as gender minorities and 79% as sexual minorities, 48.9% with 4-year college or graduate degrees, 59.4% employed, 65.9% with private insurance, 39.1% living at or below the federal poverty level, and 8.3% living with HIV. Seventy-seven percent of patients who were offered HPV vaccination had completed the series. Factors significantly associated with HPV vaccine completion included: 4-year college or graduate degree (OR: 2.87; 95% CI = 1.26-6.53), completion of primary care appointments (OR: 1.03; 95% CI: 1.01-1.05), Hepatitis A or B vaccine completion (OR: 2.59; 95% CI: 1.2-5.59), and visits for a sexually transmitted infection (STI) screen (OR: 1.22; 95% CI: 1.03-1.43). CONCLUSION: Vaccine completion was higher among SGM with higher levels of education, Hepatitis A or B vaccination, and completed health visits. These findings highlight potential ways to increase HPV vaccination, such as offering tailored HPV vaccine education, bundling with other vaccines, and incorporating HPV vaccination with STI screenings.
BACKGROUND: Disparities in human papillomavirus (HPV) vaccination completion have been noted among sexual and gender minority (SGM) people. Little is known about factors associated with HPV vaccination among SGM people. This study examines factors linked with completion of HPV vaccination among SGM patients. METHODS: We collected cross-sectional data from electronic health records (EHRs) of SGM patients receiving primary care at a Boston community health center specialized in SGM health. We employed a binomial logistic regression model to identify factors associated with 3-dose HPV vaccine completion. RESULTS:Patients were 70.3% white, with mean age of 26.3 years (SD = 2.48), 26.9% identifying as gender minorities and 79% as sexual minorities, 48.9% with 4-year college or graduate degrees, 59.4% employed, 65.9% with private insurance, 39.1% living at or below the federal poverty level, and 8.3% living with HIV. Seventy-seven percent of patients who were offered HPV vaccination had completed the series. Factors significantly associated with HPV vaccine completion included: 4-year college or graduate degree (OR: 2.87; 95% CI = 1.26-6.53), completion of primary care appointments (OR: 1.03; 95% CI: 1.01-1.05), Hepatitis A or B vaccine completion (OR: 2.59; 95% CI: 1.2-5.59), and visits for a sexually transmitted infection (STI) screen (OR: 1.22; 95% CI: 1.03-1.43). CONCLUSION: Vaccine completion was higher among SGM with higher levels of education, Hepatitis A or B vaccination, and completed health visits. These findings highlight potential ways to increase HPV vaccination, such as offering tailored HPV vaccine education, bundling with other vaccines, and incorporating HPV vaccination with STI screenings.
Authors: Brittany M Charlton; Heather L Corliss; Stacey A Missmer; A Lindsay Frazier; Margaret Rosario; Jessica A Kahn; S Bryn Austin Journal: J Adolesc Health Date: 2011-06-08 Impact factor: 5.012
Authors: Dorothy A Machalek; Mary Poynten; Fengyi Jin; Christopher K Fairley; Annabelle Farnsworth; Suzanne M Garland; Richard J Hillman; Kathy Petoumenos; Jennifer Roberts; Sepehr N Tabrizi; David J Templeton; Andrew E Grulich Journal: Lancet Oncol Date: 2012-03-23 Impact factor: 41.316
Authors: Gwendolyn P Quinn; Julian A Sanchez; Steven K Sutton; Susan T Vadaparampil; Giang T Nguyen; B Lee Green; Peter A Kanetsky; Matthew B Schabath Journal: CA Cancer J Clin Date: 2015-07-17 Impact factor: 508.702
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: Holly B Fontenot; Terrence Lee-St John; Ralph Vetters; Danielle Funk; Chris Grasso; Kenneth H Mayer Journal: Sex Transm Dis Date: 2016-12 Impact factor: 2.830
Authors: Janet R Daling; Margaret M Madeleine; Lisa Godefroy Johnson; Stephen M Schwartz; Katherine A Shera; Michelle A Wurscher; Joseph J Carter; Peggy L Porter; Denise A Galloway; James K McDougall Journal: Cancer Date: 2004-07-15 Impact factor: 6.860
Authors: R Grewal; S L Deeks; T A Hart; J Cox; A De Pokomandy; T Grennan; G Lambert; D Moore; F Coutlée; M Gaspar; C George; D Grace; J Jollimore; N J Lachowsky; R Nisenbaum; G Ogilvie; C Sauvageau; D H S Tan; A Yeung; A N Burchell Journal: Hum Vaccin Immunother Date: 2021-12-02 Impact factor: 3.452
Authors: Joanna May Kesten; Carrie Flannagan; Eimear Ruane-McAteer; Samuel William David Merriel; Tom Nadarzynski; Gilla Shapiro; Zeev Rosberger; Gillian Prue Journal: BMJ Open Date: 2019-05-14 Impact factor: 2.692
Authors: Anthony T Pho; Suzanne Bakken; Mitchell R Lunn; Micah E Lubensky; Annesa Flentje; Zubin Dastur; Juno Obedin-Maliver Journal: J Am Med Inform Assoc Date: 2022-01-12 Impact factor: 4.497